Human Chorionic Gonadotropin Market By Treatment (Female Infertility Treatment, Oligospermia Treatment, Cryptorchidism Treatment), By Technology (Natural Source Extraction, Recombinant Dna Technology) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Fertility patterns worldwide have changed dramatically and a rise in the infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.

This report studies the global human chorionic gonadotropin (HCG) market based on use of human chorionic gonadotropin in various treatments and production technologies. HCG is widely used for female infertility treatment, oligospermia, and cryptorchidism treatments. Based on manufacturing technologies the HCG market is categorized into natural source extraction and recombinant DNA technology. This report studies these segments in terms of their historical and future market size and forecast for the period 2014-2022. Respective compounded annual growth rates (CAGR %) for these segments for the period 2016-2022 are also presented in this study.

Geographically, the global human chorionic gonadotropin market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Middle East and Africa
  • Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 are also provided in this report.

Qualitative information such as drivers, restraints and future opportunities for the global hospital-acquired disease testing market are included in this report. Competition assessment tools such as competition analysis and attractive investment proposition are presented in this study for scrutinizing competition of the global human chorionic gonadotropin market. This study concludes with the company profiles section that highlights information about the key companies engaged in development, manufacture and provision of human chorionic gonadotropin products.

Based on geographical segmentation, the human chorionic gonadotropin market is studied for:

  • North America
    • US
    • Canada 
  • Europe
    • UK
    • Germany
    • Fance
    • Rest of Europe
  • Asia-Pacific
    • Japa
    • China
    • India
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa

Human Chorionic Gonadotropin Market

North America is expected to be the largest and most potential regional market for human chorionic gonadotropin. North America constitutes regional markets of U.S.and Canada, the rising incidence of infertility cases, lifestyle effects and others, hormonal dysfunctions in men and women are the major driver for the growth of the global human chorionic gonadotropin market. Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by2022. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centred in Japan, South Korea, China, and India. Numerous factors such as developing economical landscape, increasing disposable incomes, growing public awareness related to infertility therapy, and increasing government support through providing favourable policies are the major factors expected to assist the growth of Asia-Pacific market.

Choose License Type
Published Date:  Jul 2016
Category:  Pharmaceuticals
Report ID:   57982
Report Format:   PDF
Pages:   120
Rating:    4.4 (65)
Connect With Us
+1-408-641-3282
24/7 Research Support